Based on the fully human antibody transgenic RenMab™, RenLite™, and RenNano™ Mice, Biocytogen has integrated its technology platforms in single-cell antibody discovery, gene editing, large-scale disease mouse model supply, and in vivo pharmacology screening to form a new approach to streamline the entire antibody drug discovery and development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit www.biocytogen.com
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Ultivue’s InSituPlex® technology eliminates the need for assay development and enables scientists to unmask and analyze the true biological context of tissue samples. UltiMapper™ kits are fully optimized mIHC panels that provide uninhibited co-localization of multiple markers for deep single-cell phenotyping.
Committed to healthcare since 2004, LARVOL has been delivering custom intelligence solutions that provide healthcare and life sciences experts accurate, rapid, expertly-curated information to enable strategic decision-making. Specifically in the oncology space, we collate and simplify data from over 25,000 sources and offer novel tools to extract meaningful insights. Our newest product CLIN delivers the complete universe of immuno-oncology clinical trial data in one, easy-to-navigate platform. That's ten years of trial data, manually reviewed and coded to extract every table, graph, and figure. New data is added as it's released from publications, conferences, and guidelines.
Proteome Sciences is a CRO specializing in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterize proteins and their associated post-translational modifications. By using LC-MS2, SysQuant®, and TMTcalibratorTM methodologies we can detect up to 8,000 of proteins/sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up- or down-regulated with disease progression or drug treatment.
GemPharmatech is a global company providing high-quality products and model systems for discovery, testing, development and production of new drugs and therapeutic solutions. GemPharmatech is one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners across the world. With advance gene editing technology, GemPharmatech has created and produced a large collection of over 14,000 transgenic mouse models for therapeutic applications.
Sino Biological is dedicated in providing the scientific community with high-quality recombinant protein and antibody reagents to promote life science research and drug discovery. The company has the biggest validated recombinant protein bank (6000+) in the world covering existing immune-oncology drug targets, cytokines, and viral proteins. Several robust recombinant protein expression platforms and antibody discovery methods have been established and are available for customized contracted research projects.
Quanterix™ Corporation is digitizing biomarker analysis with the goal of advancing the science of precision healthcare. Our ultra-sensitive technology platform, Simoa®, enables researchers to quantify a range of disease biomarkers at lower levels than ever before, in most common sample types. Simoa’s ultra-sensitivity, multiplex detection capability and flexibility in custom assay development are advancing both academic research and drug development both in our customers' own facilities and by contract in our CLIA-certified Quanterix Accelerator Laboratory.
NeoGenomics is an industry-leading cancer diagnostics and pharma services company. We enable advanced oncology patient care leveraging the most extensive diagnostic solid tumor and hematological test menus, sub-specialized pathology, and expertise in biomarker development. We partner closely with our pharma and research clients to meet program objectives and delivery from biomarker discovery through CDx validation and commercialization.
PHC Holdings Corporation is a global healthcare company with its products and services used in more than 125 countries. Subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia and LSI Medience Corporation. The company develops, manufactures, sells and services medical equipment and solutions across the diabetes management, diagnostics, life sciences and healthcare services. Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics. URL: www.phchd.com
TransCure bioServices (TCS) provides predictive in vivo pharmacology expertise for drug pre-clinical candidate selection in the fields of infectious, cancer (IO, PDX), inflammation, vaccine and immune disease areas. We are the only preclinical CRO providing commercially HIV, immuno-oncology (IO) therapy, PDX, IBD, vaccine and autoimmune mouse models with a fully functional reconstituted HUMAN IMMUNE SYSTEM (hu-mouse models). We co-design study protocols/experiments performing the ordered studies and providing comprehensive data collection, data analysis and reports.
“ CELLINK began as the first bioink company in the world. Today, we’re the global leader for designing and commercializing bioprinting technologies. Our innovations enable researchers to 3D print organs and tissue for applications that span industries, from pharmaceutical to cosmetic. From bioinks to bioprinting and cell dispensing to live cell imaging, we’re committed to supporting our collaborators with state-of-the-art capabilities to change the future of medicine. To read more about CELLINK, visit www.cellink.com.”
evorion biotechnologies offers custom development services and access to a unique, proprietary functional phenomics pipeline for in-depth multi-parametric analysis of thousands of cell-cell interactions at single-cell resolution. For the first time, researchers can connect a single cell’s functional phenotype with multi-omics data, opening up a new realm of novel insights into cancer-immune cell interactions that will revolutionize cell therapies. Let us partner in advancing human medicine by developing the next generation of adoptive cell therapies.
We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno oncology.
Our proprietary AI target discovery engine is called “Diamond.”
Diamond is AI big data science meeting target identification, dramatically compressing man years and billions of drug development dollars to develop a live drug.
Our first product is Alexis-Pro and Alexis-ISO, off-the-shelf allogenic chPD1, and iso-mesothelin CAR-T(s) for solid tumor.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
For its Biopharma partners, HalioDx has developed the Immunogram, a clinical research platform allowing multimodal analysis to understand the tumor microenvironment. It integrates Immunoscore® assays, innovative technologies like Multiplex Spatial Tissue Analysis (Brightplex®) and molecular testing (NGS, Immunosign® Gene Expression Signatures).
IDDI provides biostatistical and eClinical services to pharmaceutical and biotech companies since 1991.
Predicine is a molecular insights company committed to advancing biomarker-driven precision medicine. It has developed a breakthrough cell-free DNA and cell-free RNA based liquid biopsy technology for non-invasive cancer profiling, disease monitoring, assessing MRD, and early cancer detection. Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer care.
Altis Biosystems has a patent-pending stem cell platform that recreates the human intestinal epithelium in a high-throughput format for drug screening and microbiome research. Altis provides a variety of services including, Inflammation, Barrier Function, Toxicology, and Drug Disposition and also sells the platform as a kit. Our goal is to reduce the time and cost of drug development with a platform that more accurately reflects native human biology and reduce the need for animal testing.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.